1. Home
  2. TROO vs AGEN Comparison

TROO vs AGEN Comparison

Compare TROO & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TROOPS Inc.

TROO

TROOPS Inc.

HOLD

Current Price

$1.65

Market Cap

151.5M

Sector

Technology

ML Signal

HOLD

Logo Agenus Inc.

AGEN

Agenus Inc.

HOLD

Current Price

$3.83

Market Cap

126.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TROO
AGEN
Founded
2005
1994
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Radio And Television Broadcasting And Communications Equipment
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
151.5M
126.8M
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
TROO
AGEN
Price
$1.65
$3.83
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$14.50
AVG Volume (30 Days)
55.9K
456.3K
Earning Date
12-04-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$15,084,000.00
$106,829,000.00
Revenue This Year
N/A
$67.15
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
247.24
N/A
52 Week Low
$0.49
$1.38
52 Week High
$2.62
$7.34

Technical Indicators

Market Signals
Indicator
TROO
AGEN
Relative Strength Index (RSI) 70.41 38.61
Support Level $1.21 $3.82
Resistance Level $1.75 $4.12
Average True Range (ATR) 0.18 0.20
MACD 0.04 -0.04
Stochastic Oscillator 86.89 0.58

Price Performance

Historical Comparison
TROO
AGEN

About TROO TROOPS Inc.

TROOPS Inc is a conglomerate group of various businesses with its headquarters based in Hong Kong. The group is principally engaged in money lending business in Hong Kong providing mortgage loans to high quality target borrowers, property investment to generate additional rental income and the development, operation and management of an online financial marketplace that provides one-stop financial technology solutions including API services by leveraging artificial intelligence, large data and blockchain, and cloud computing (SaaS). It derives revenue from Hong Kong and Australia. Majority of its revenue generates from domestic market.

About AGEN Agenus Inc.

Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

Share on Social Networks: